

Updated: May 2024 Page 1 of 8

PATHWAY PRIMER

Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout is increasing in incidence and prevalence and is the **most common cause of inflammatory arthritis in men over 40** years of age. It is **very rare in premenopausal women**. Gout is a **curable disease** that is vastly undertreated worldwide, mainly due to misconceptions regarding urate lowering therapy, resulting in permanent joint damage and disability. Poor adherence to therapy is common, and patients require ongoing education and monitoring. Hyperuricemia and gout are strongly associated with hypertension, the metabolic syndrome, renal impairment and cardiovascular disease.

Clinical Features: Classic acute gout typically affects one joint but several joints can also be involved. The most commonly involved areas (in decreasing frequency) are: the first MTP ("podagra"), instep, ankle, heel, knee, wrist, fingers and elbow. Gout can also affect bursae, especially over the elbows, knees or Achilles tendon. The affected joint and surrounding soft tissues are **exquisitely painful**, **warm**, **red and swollen**, and can resemble cellulitis. Patients may not be able to tolerate even a bed sheet touching the affected joint and may be unable to walk. The attacks usually last 3 to 10 days, and **peeling of the skin** over the joint may occur as the attack resolves. Without urate lowering therapy, the attacks may increase in frequency, involve multiple joints, persist longer and deposits of uric acid in the soft tissues (tophi) will occur. **Tophi are strongly associated with destructive and deforming joint disease**.

EXPANDED DETAILS

Dietary	Excess alcohol, purines (meat, seafood), fructose (soda, juice, energy drinks)
Drugs / iatrogenic	Diuretics, low dose ASA, chemotherapy, radiation
Acute medical illness	Hemorrhage, infection, renal insufficiency, dehydration, surgery
Trauma	Injury to joint (may be minor)
Endocrine	Thyroid (hypo/hyper), hyperparathyroidism and uncontrolled diabetes

Potential triggers of gout attacks:

Diagnosis: Although the **gold standard test is identification of uric acid crystals in fresh synovial fluid** on polarized microscopy, this may not be feasible in some patients, or in a primary care setting. **Serum uric acid levels can be normal during an acute gout attack**, but will be elevated at some point in almost all gout patients. Although not all hyperuricemic patients have gout, the risk of gout is high with persistent serum urate levels >580 umol/L. X-rays are NOT useful for making an early diagnosis before permanent damage occurs. However, classic marginal erosions are often present on those with a long clinical history. Ultrasound can demonstrate active inflammation while Dual energy CT is an emerging technology that is very useful in demonstrating MSU crystal deposition in diagnostic dilemmas. Diagnostic dilemmas should be referred to Rheumatology.

If synovial fluid analysis is not possible, diagnostic algorithms may help to determine whether the probability of gout is low, intermediate or high. The **"Gout Diagnosis Calculator**" was developed for this purpose (see Links below for free app). If the probability is intermediate, the patient should be followed closely and synovial fluid analysis



performed when possible. The ACR-EULAR Gout Classification Criteria Calculator (see Links below for URL) is another helpful diagnostic tool for gout.

Checklist to guide your in-clinic review of this patient with gout symptoms:

- □ Is history consistent with typical gout attacks? Consider using diagnostic tool (see link below)
- □ Are there any red flags to suggest infection?
- Does the patient have a history of kidney stones, or tophi on examination?
- □ Are there any potential gout triggers, including lifestyle factors?
- □ Review and treat modifiable cardiac risk factors.

General principles

- All patients with gout should be fully informed of the causes of gout, management principles & lifestyle modifications (including weight loss, regular exercise, alcohol use and diet)
- Screen all patients for comorbidities including renal impairment and cardiovascular risk factors
- Treat acute attacks as soon as possible; early treatment can prevent a full blown attack
- Gout generally cannot be managed with diet alone, but can be cured with a combination of diet control and urate lowering therapy.
- ~40% of urate is from diet; 60% is a normal waste product (blocked by allopurinol or febuxostat)

Dietary advice for gout

Patients should limit consumption of	- meats, especially organ meat (liver, kidney etc.)
	- seafood, especially shellfish, sardines and anchovies
	- alcohol, especially beer
Moderate intake of other purine-rich foods should	- purine-rich vegetables (asparagus, cauliflower,
not aggravate gout	spinach, mushrooms)
	- nuts
	- legumes (beans and peas)
Intake of the following may reduce the risk of gout	 coffee (use decaffeinated if > 2 cups/day)
attacks	- vitamin C (500 mg/day)
	- low fat dairy (milk, yoghurt)
	- tart cherries (not in pill form)

Treatment of acute gout attacks

Treatment	Dosage	Comments
Oral colchicine	 0.6 mg po BID until attack subsides 0.3 mg OD - BID if GFR 30–50 mL/min more effective if started within the first 36 hr of an attack 	 contraindicated if severe renal (GFR <30 mL/min) or hepatic insufficiency DO NOT use old regimens with frequent doses until patient has diarrhea use caution if on immunosuppressive drugs due to potential drug interactions
Corticosteroids	- prednisone 30 mg PO OD x 5 days OR - Kenalog® (triamcinolone acetonide) 1 mg/kg or 80 mg IM x 1	- can be used safely in chronic kidney disease - safer than NSAIDs or colchicine in the elderly

	into gluteal muscle (use a 22 G x 1.5 inch needle)	
NSAIDs	 - indomethacin 25-50 mg TID, <u>OR</u> - naproxen 250-500 mg BID - then taper off after symptoms subside 	 often contraindicated due to comorbidities other NSAIDs (full dose) may be as effective as indomethacin consider gastroprotection
Intraarticular steroids	 40 - 80 mg of triamcinolone (Kenalog®) for larger joints 10 - 20 mg of methylprednisolone (DepoMedrol ®) for small joints or bursae 	 useful in treatment of 1 or 2 involved joints sometimes more effective than oral corticosteroids aspirating excess synovial fluid prior to injection of steroid has therapeutic benefit synovial fluid aspirate should be sent to lab for cell count, culture, and crystals

Treatment of chronic gout

A. Indications for urate lowering therapy (Note: Treatment is usually LIFELONG!)

- More than 2 or 3 acute attacks of gout within 1 to 2 years (or unremitting gouty inflammation)
- Radiographic evidence of joint damage due to gout (x-ray, ultrasound or dual energy CT)
- Presence of tophi
- Established gout with chronic kidney disease stage 2 or worse (GFR <90 mL/min)
- Renal stones (urate)

B. Gout Flare Prophylaxis (Mandatory while initiating urate lowering therapy)

- Continue colchicine prophylaxis for:
 - o 3 months after achieving the serum uric acid goal in patients without tophi, OR
 - $_{\odot}$ 6 months after achieving the serum uric acid goal in patients with 1 or more tophi, OR
 - o continue prophylaxis for longer if acute gout flares persist
- It is common practice to treat with BOTH corticosteroids (single IM dose or short course PO) AND colchicine when initiating urate lowering therapy.

Colchicine	0.6 mg po OD or BID, or 0.3 mg po OD or BID if elderly or GFR 30 to 50 mL/min Do not use if GFR < 30 mL/min
Corticosteroids	 Kenalog® (triamcinolone acetonide) 80 mg IM deep into gluteal muscle, <u>OR</u> Prednisone 20 mg PO OD in patients with contraindications to NSAIDs and colchicine, taper by 5mg per week
NSAID	e.g. naproxen 250 mg to 500 mg po BID with a proton pump inhibitor Potential for significant side effects if comorbidities (renal disease, elderly) Avoid prophylaxis with combination of NSAIDs and oral prednisone

C. Initiation of Urate Lowering Therapy (Target: serum urate < 360 umol/L; <300 umol/L if tophi)

- Allopurinol 300 mg PO OD can be started in patients on prophylaxis with steroids and colchicine.
- Alternatively, the dose can be slowly titrated up to minimize the risk of gout attacks as follows:
 - o Allopurinol 100 mg PO OD x 2 to 4 weeks →
 - o Allopurinol 200 mg PO OD x 2 to 4 weeks →
 - Allopurinol 300 mg PO OD thereafter (300 mg is sufficient for most; cost ~33¢ per tablet) →
 - $_{\odot}$ Allopurinol dose may be increased to 400 mg if serum urate level remains above target \rightarrow

• Refer to Rheumatology if not responding.

- CBC, CRP, Cr, ALT, albumin, uric acid monthly until urate stable, then every 6 to 12 months
- Febuxostat 80 mg PO OD or every other day can be used instead of allopurinol in patients with stage 4 or 5 CKD (GFR < 30 mL/min), or other contraindications to allopurinol. Blue Cross requires a special authorization form (cost ~\$1 per tablet), but most private insurers do not.

Contraindications/Reasons to stop urate lowering therapy

The vast majority will tolerate allopurinol well. The most common concern is an \uparrow in gout attacks during initiation of treatment, such that gout prophylaxis is mandatory. **DO NOT stop allopurinol for a gout attack. Allopurinol and febuxostat should not be used in patients on azathioprine** (Imuran®) due to the risk of bone marrow failure (refer to rheumatology). Patients with **allopurinol hypersensitivity** (rash, fever, \downarrow platelets, \uparrow liver enzymes) should stop immediately and never take this drug again.

HLA-B*58:01 testing for ethnic groups at risk for hypersensitivity reactions

Chinese, Thai and Korean patients are at risk for life-threatening allopurinol hypersensitivity reactions. HLA-B*5801 screening should be considered in these patients before starting allopurinol, and if positive allopurinol should not be used. This genetic test can be ordered through CLS. High-risk individuals should be treated with febuxostat instead.

BACKGROUND

About this pathway

• The pathway is intended to provide evidence-based guidance to support primary care and specialty care providers in caring for adult patients with gout within the medical home. Rheumatology tele-advice is available via <u>Specialist</u> <u>Link</u> (see advice section under Provider Resources).

Authors and conflict of interest declaration

• This pathway was developed by leveraging the collective knowledge, experience and expertise of many individuals. See a full list below. For more information, please email <u>info@calgaryareapcns.ca</u>.

Faculty	Names
Associate Professor of Medicine Section of Rheumatology	Susan Barr MD, MSc, FRCPC
Clinical Associate Professor Section of Rheumatology	Paul MacMullan MD, MB BCh, BAO, MRCPI
Section Chief Community Primary Care Department of Family Medicine Alberta Health Services – Calgary Zone	Monica Sargious MD, CCFP, FCFP
Medical Director, Mosaic Primary Care Network	Oliver David MD, CCFP

Pathway review process, timelines

• Primary care pathways undergo scheduled review every three years, or earlier if there is a clinically significant change in knowledge or practice. This pathway was developed in September 2017 and was most recently updated in May 2024. The next scheduled review is May, 2026. However, we welcome feedback at any time. Please email comments to info@calgaryareapcns.ca with "Gout Pathway" in the subject line.

Copyright information

This work is licensed under a Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International license. You are free to copy, distribute and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services and Primary Care Networks and abide by the other license terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible license. The license does not apply to content for which the Alberta Health Services is not the copyright owner.



DISCLAIMER

This pathway represents evidence-based best practice but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients' specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.



PROVIDER RESOURCES

Advice options

- Non-urgent telephone advice connects family physicians, nurse practitioners and specialists in real time via a tele-advice line. Family physicians, nurse practitioners and specialists can request non-urgent advice from a rheumatologist, at <u>specialistlink.ca</u> or by calling 403-910-2551. This service is available from 8 a.m. to 5 p.m. Monday to Friday (excluding statutory holidays). Calls are returned within two (2) hours.
- Non-urgent rheumatology electronic advice is available across the province via Alberta Netcare eReferral eConsult (responses are received within five calendar days). View the <u>eReferral Learning Centre</u> for more information.

Resources	Location	
Gout information	http://rheuminfo.com/diseases/gout	
National Institute of Arthritis and Musculoskeletal and Skin Diseases	https://www.niams.nih.gov/health Info/Gout/default.asp	
Screening tools		
Diagnostic rule for gout without joint fluid analysis: Download "Gout Diagnosis Calculator" free from the App Store or use this online tool	https://www.mdcalc.com/acute-gout-diagnosis-rule	
Classification criteria for gout - Online tool	http://goutclassificationcalculator.auckland.ac.nz/	

PATIENT RESOURCES

Information

Resource type	Resource name	Location
Website	Gout information	www.rheuminfo.com/diseases/gout
Website	Gout education	www.gouteducation.org
Handout	Gout education	https://www.albertahealthservices.ca/assets/info/n utrition/if-nfs-healthy-changes-for-managing- gout.pdf